TNX-355 With Optimized Background Therapy (OBT) in Treatment-Experienced Subjects With HIV-1
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This is a 48-week study to compare TNX-355 plus OBT to placebo plus OBT in HIV subjects. You
must have a stable viral load of at least 10,000 copies/ml, been treated with highly active
antiretroviral therapy (HAART) for at least 6 months, be triple class experienced, and
presently failing or have failed a HAART regimen. Subjects will receive infusions every week
for 8 weeks, then every two weeks.